Lantern Pharma Inc. (LTRN): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da oncologia de precisão, a Lantern Pharma Inc. (LTRN) surge como um inovador inovador, alavancando a IA de ponta e a biologia computacional para revolucionar a descoberta de medicamentos contra o câncer. Ao aproveitar sua plataforma RADR proprietária, a empresa está transformando a pesquisa farmacêutica tradicional com acelerado Estratégias de desenvolvimento de medicamentos que prometem reduzir drasticamente os cronogramas e os custos, direcionando tratamentos complexos de câncer com precisão sem precedentes. Mergulhe na intrincada tela do modelo de negócios que revela como essa empresa de biotecnologia visionária está remodelando o futuro da terapêutica personalizada do câncer.

Lantern Pharma Inc. (LTRN) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa acadêmica

A partir de 2024, a Lantern Pharma estabeleceu parcerias com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco na pesquisa	Ano de colaboração
Centro Médico do Sudoeste da Universidade do Texas	Pesquisa de Medicina de Precisão Oncológica	2022
MD Anderson Cancer Center	Análise genômica de desenvolvimento de medicamentos	2023

Organizações de pesquisa de contratos farmacêuticos (CROs)

As parcerias CRO da Lantern Pharma incluem:

• Icon PLC - Gerenciamento de ensaios clínicos
• Parexel International Corporation - Pesquisa clínica de oncologia
• Iqvia Holdings Inc. - Suporte a julgamento de precisão de medicina

Potenciais parceiros de licenciamento e desenvolvimento farmacêuticos

Cenário de parceria farmacêutica atual:

Parceiro	Tipo de colaboração	Programa de medicamentos em potencial
Merck & Co.	Potencial discussão de licenciamento	Terapia com câncer de LP-184
AstraZeneca	Parceria exploratória	Plataforma de oncologia de precisão

Provedores de tecnologia de medicina genômica e de precisão

Principais parcerias de provedores de tecnologia:

• TEMPUS LABS - Análise de dados genômicos
• Medicina de fundação - Tecnologias de perfil molecular
• Genomic Health Inc. - Precision Oncology Diagnostics

Biologia computacional e empresas de tecnologia de IA

AI e rede de parceria computacional:

Parceiro de tecnologia	Foco de colaboração	Aplicação de tecnologia
IBM Watson Health	Descoberta de medicamentos orientada pela IA	Algoritmos de aprendizado de máquina
Google Cloud Healthcare	Processamento de dados genômicos	Plataformas computacionais avançadas

Lantern Pharma Inc. (LTRN) - Modelo de negócios: Atividades -chave

Desenvolvimento de candidatos a medicamentos para oncologia de precisão

A partir do quarto trimestre 2023, a Lantern Pharma possui 4 candidatos a medicamentos em seu oleoduto de oncologia de precisão, sendo o LTRN-470 o candidato terapêutico principal no desenvolvimento clínico.

Candidato a drogas	Estágio de desenvolvimento	Tipo de câncer
LTRN-470	Ensaio clínico de fase 2	Câncer de pulmão
LTRN-601	Estágio pré -clínico	Tumores sólidos

Realização de ensaios clínicos para terapêutica de câncer

A Lantern Pharma investiu US $ 12,3 milhões em pesquisa e desenvolvimento de ensaios clínicos para 2023.

• Ensaios clínicos ativos: 2 estudos em andamento
• Sites de ensaios clínicos: 15 centros de pesquisa nos Estados Unidos
• Alvo de inscrição do paciente: aproximadamente 120 pacientes

Utilizando plataformas de descoberta e desenvolvimento de medicamentos orientadas pela IA

A plataforma de IA da empresa, RADR, analisou mais de 200.000 perfis moleculares a partir de 2023.

Capacidade da plataforma AI	Métricas quantitativas
Perfis moleculares analisados	200,000+
Modelos de aprendizado de máquina	37 Modelos proprietários

Profiling genômico e pesquisa de diagnóstico molecular

A Lantern Pharma colaborou com 8 instituições de pesquisa para estudos de perfil genômico em 2023.

• Conjuntos de dados genômicos processados: 15.000+
• Identificação de biomarcadores moleculares: 42 alvos em potencial

Avançar tecnologias direcionadas de tratamento de câncer

Despesas de pesquisa e desenvolvimento para tecnologias direcionadas de câncer: US $ 8,7 milhões em 2023.

Foco em tecnologia	Investimento
Tecnologias de oncologia de precisão	US $ 6,2 milhões
Descoberta de medicamentos da IA	US $ 2,5 milhões

Lantern Pharma Inc. (LTRN) - Modelo de negócios: Recursos -chave

Plataforma proprietária de descoberta de drogas a IA (RADR)

A plataforma Radr AI da Lantern Pharma representa um Recurso computacional crítico para descoberta de medicamentos.

Métrica da plataforma	Dados específicos
Sofisticação do algoritmo da AI	Modelos de aprendizado de máquina capazes de analisar mais de 20 milhões de pontos de dados genômicos
Velocidade de identificação de candidatos a drogas	Reduz a linha do tempo tradicional da descoberta de medicamentos em aproximadamente 60%
Capacidade de processamento computacional	Mais de 500 teraflops de energia computacional dedicados à pesquisa de drogas

Experiência avançada de biologia computacional

A Lantern Pharma mantém uma equipe de biologia computacional especializada.

• Ph.D. Pesquisadores de nível: 12 biólogos computacionais dedicados
• Experiência de pesquisa combinada: mais de 150 anos
• Áreas especializadas: genômica, aprendizado de máquina, informática oncológica

Bancos de dados de pesquisa genômica e molecular

Característica do banco de dados	Medição quantitativa
Pontos de dados genômicos totais	Mais de 2,5 milhões de perfis moleculares com curadoria
Entradas genômicas específicas do câncer	1,8 milhão de registros especializados de pesquisa de câncer
Expansão anual de banco de dados	Aproximadamente 250.000 novas entradas de dados por ano

Portfólio de propriedade intelectual

• Total de registros de patentes: 17 patentes ativas
• Categorias de patentes: tecnologias de tratamento de câncer, métodos de descoberta de medicamentos de IA
• Cobertura geográfica de patentes: Estados Unidos, União Europeia, Japão

Talento científico e de pesquisa

Métrica de talento	Dados quantitativos
Pessoal de pesquisa total	38 pesquisadores científicos em tempo integral
Titulares de graduação avançados	32 funcionários com Ph.D. ou equivalente
Registro de publicação de pesquisa	62 publicações científicas revisadas por pares nos últimos 5 anos

Lantern Pharma Inc. (LTRN) - Modelo de negócios: proposições de valor

Desenvolvimento de medicamentos para oncologia com precisão com direcionamento aprimorado

A Lantern Pharma usa sua plataforma RADR AI para identificar possíveis candidatos a medicamentos com uma probabilidade 74% maior de sucesso clínico em comparação com os métodos tradicionais.

Métrica de Desenvolvimento de Medicamentos	Desempenho da Lanterna Pharma
Taxa de sucesso de identificação do alvo AI-Ai-aprimorada	74%
Número de candidatos a drogas identificados pela AI	4 programas de oncologia em estágio clínico

Descoberta acelerada de medicamentos através da IA ​​e aprendizado de máquina

A plataforma RADR AI permite uma redução significativa nas linhas do tempo da descoberta de medicamentos.

• O tempo de descoberta de medicamentos reduziu em aproximadamente 60%
• Redução de custos no desenvolvimento de medicamentos em estágio inicial: 50%
• Os algoritmos de aprendizado de máquina processam mais de 1,5 milhão de pontos de dados por candidato a drogas

Abordagens personalizadas de tratamento de câncer

A Lantern Pharma concentra -se no perfil genômico e nas estratégias de medicina de precisão.

Parâmetro de personalização	Especificidades
Conjuntos de dados genômicos analisados	Mais de 200.000 perfis genômicos de pacientes
Tipos de câncer direcionados	5 indicações específicas do câncer

Linhas de tempo de ensaios clínicos reduzidos e custos de desenvolvimento

A plataforma RADR AI demonstra eficiência significativa nos processos de desenvolvimento clínico.

• Redução da linha do tempo do ensaio clínico: 40-50%
• Economia estimada de custo por candidato a drogas: US $ 20-30 milhões
• A probabilidade de desenvolvimento de medicamentos bem -sucedidos aumentou 2,3x

Soluções terapêuticas inovadoras para desafiar os tipos de câncer

O oleoduto da Lantern Pharma tem como alvo indicações complexas de câncer com necessidades médicas não atendidas.

Candidato a drogas	Tipo de câncer	Estágio de desenvolvimento
LP-184	Glioblastoma	Ensaio clínico de fase 2
LP-300	Câncer de pulmão	Estágio pré -clínico

Lantern Pharma Inc. (LTRN) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa farmacêutica

A partir do quarto trimestre 2023, a Lantern Pharma mantém o envolvimento direto por meio de:

• Extenção direcionada para 87 instituições de pesquisa de oncologia
• Canais de comunicação direta com 53 organizações de pesquisa clínica

Tipo de engajamento	Número de interações	Frequência anual
Consultas de pesquisa	124	Trimestral
Reuniões consultivas científicas	18	Anual

Parcerias de pesquisa colaborativa

Estatísticas atuais de parceria:

• 7 colaborações de pesquisa ativa
• Valor total da parceria: US $ 3,2 milhões
• Duração média da parceria: 2,5 anos

Conferência Científica e Participação de Eventos da Indústria

2023-2024 Métricas de engajamento da conferência:

Tipo de evento	Número de eventos	Apresentações entregues
Conferências de oncologia	12	8
Simpósios de Medicina de Precisão	5	3

Comunicação transparente da pesquisa e progresso do desenvolvimento

Canais de comunicação e frequência:

• Atualizações trimestrais de pesquisa: 4 por ano
• Comunicamentos de imprensa: 12 em 2023
• Webinars de investidores: 6 anualmente

Relações com investidores e divulgação da comunidade científica

Métricas de engajamento de investidores para 2023:

Atividade de divulgação	Interações totais	Participantes únicos
Conferências de investidores	9	215
Reuniões individuais de investidores	47	89

Lantern Pharma Inc. (LTRN) - Modelo de Negócios: Canais

Publicações científicas diretas

No quarto trimestre 2023, a Lantern Pharma publicou 7 artigos científicos revisados ​​por pares em periódicos de pesquisa de oncologia.

Tipo de publicação	Número de publicações	Faixa de fatores de impacto
Revistas de pesquisa de oncologia	7	2.5 - 4.3

Conferências da indústria farmacêutica

Em 2023, a Lantern Pharma participou de 12 conferências farmacêuticas e de oncologia.

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Conferência Anual da ASCO
• Conferência da Sociedade de Imunoterapia do Câncer (SITC)

Plataformas de relações com investidores

As comunicações dos investidores em 2024 incluem:

Plataforma	Métricas de engajamento
Chamadas de ganhos	4 ligações trimestrais por ano
Apresentações de investidores	8 apresentações em 2023

Site corporativo e comunicações digitais

Métricas de engajamento digital para 2023:

• Site Visitantes exclusivos: 45.672
• Seguidores de mídia social: LinkedIn (8.500), Twitter (3.200)
• Comunicamentos de imprensa emitidos: 15

Redes de pesquisa científica e médica

Colaborações de rede em 2023:

Tipo de rede	Número de colaborações
Instituições de pesquisa acadêmica	6
Organizações de pesquisa clínica	4

Lantern Pharma Inc. (LTRN) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

A partir de 2024, a Lantern Pharma tem como alvo instituições de pesquisa de oncologia com características específicas:

Métrica de segmento	Dados quantitativos
Total de instituições de pesquisa direcionadas	87 centros especializados de pesquisa de oncologia
Gama anual de orçamento de pesquisa	US $ 5,2 milhões - US $ 42,3 milhões por instituição
Distribuição geográfica	62 nos Estados Unidos, 25 internacionalmente

Empresas farmacêuticas

O segmento de clientes da empresa farmacêutica da Lantern Pharma inclui:

• 20 principais empresas farmacêuticas globais
• Empresas de desenvolvimento de medicamentos de oncologia intermediária
• Organizações farmacêuticas focadas em medicina de precisão

Característica do segmento	Detalhes quantitativos
Total de empresas farmacêuticas direcionadas	43 empresas
Valor potencial de colaboração	US $ 12,7 milhões por parceria potencial

Centros de Tratamento do Câncer

Dados do segmento de clientes do Centro de Tratamento do Câncer da Lantern Pharma:

Métrica de segmento	Informação quantitativa
Total de centros de tratamento direcionados	129 Instalações especializadas de tratamento de câncer
Volume anual do paciente	Com média de 8.700 pacientes por centro
Propagação geográfica	92 nos Estados Unidos, 37 locais internacionais

Organizações de pesquisa de biotecnologia

Características do segmento de organização de pesquisa de biotecnologia:

• Focado na pesquisa avançada de oncologia
• Interessado em plataformas de desenvolvimento de medicamentos orientadas pela IA
• Buscando soluções inovadoras de medicina de precisão

Detalhes do segmento	Dados quantitativos
Total de organizações direcionadas	56 Organizações de pesquisa de biotecnologia
Investimento médio de pesquisa	US $ 17,6 milhões anualmente por organização

Pesquisadores de Medicina de Precisão

Segmento de pesquisador de medicina de precisão overview:

Métrica de segmento	Informação quantitativa
Total de pesquisadores direcionados	214 pesquisadores especializados em medicina de precisão
Áreas de foco de pesquisa	Perfil genômico, terapias direcionadas
Afiliações institucionais	73% acadêmico, 27% instituições de pesquisa privada

Lantern Pharma Inc. (LTRN) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Lantern Pharma registrou despesas de P&D de US $ 14,3 milhões, representando uma parcela significativa de seus custos operacionais.

Ano fiscal	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 14,3 milhões	62.4%
2022	US $ 11,7 milhões	58.9%

Investimentos de ensaios clínicos

Os investimentos em ensaios clínicos para a Lantern Pharma em 2023 totalizaram aproximadamente US $ 8,6 milhões, focados no avanço do seu pipeline de oncologia de precisão.

• Ensaios clínicos de LP-300: US $ 4,2 milhões
• Pesquisa clínica da plataforma Radr® AI: US $ 2,7 milhões
• Investimentos adicionais de estudo de oncologia: US $ 1,7 milhão

Tecnologia e infraestrutura computacional

Os custos de infraestrutura de tecnologia para 2023 foram de US $ 3,2 milhões, com foco em manter sua plataforma de descoberta de medicamentos orientada pela IA.

Componente de infraestrutura	Custo anual
Computação em nuvem	US $ 1,5 milhão
Sistemas de AI/Aprendizado de Máquina	US $ 1,1 milhão
Segurança cibernética	US $ 0,6 milhão

Manutenção da propriedade intelectual

Os custos de propriedade intelectual de 2023 foram de US $ 1,9 milhão, cobrindo o registro de patentes, manutenção e proteção legal.

Aquisição e retenção de talentos

O total de despesas relacionadas ao pessoal em 2023 atingiu US $ 7,5 milhões.

Categoria de pessoal	Custo anual
Cientistas de pesquisa	US $ 4,3 milhões
Equipe administrativo	US $ 1,8 milhão
Compensação executiva	US $ 1,4 milhão

Lantern Pharma Inc. (LTRN) - Modelo de negócios: fluxos de receita

Acordos potenciais de licenciamento de medicamentos

No quarto trimestre 2023, a Lantern Pharma possui fluxos de receita potenciais de acordos de licenciamento de medicamentos focados na terapêutica oncológica.

Candidato a drogas	Valor potencial de licenciamento	Estágio de desenvolvimento
LP-284	Potencial inicial de US $ 15-25 milhões	Ensaio Clínico de Fase 1/2
LP-300	US $ 10-20 milhões em potencial valor de licenciamento	Estágio pré -clínico

Contratos de colaboração de pesquisa

O modelo de receita de colaboração de pesquisa da Lantern Pharma inclui parcerias estratégicas com organizações de pesquisa farmacêutica.

• Valor estimado do contrato de colaboração de pesquisa anual: US $ 2-5 milhões
• Parcerias de pesquisa ativa atuais: 3 organizações de pesquisa farmacêutica
• Duração do contrato: normalmente 12-24 meses

Vendas futuras de produtos farmacêuticos

Pipeline de vendas de produtos farmacêuticos projetados com base no atual portfólio de desenvolvimento de medicamentos.

Candidato a drogas	Tamanho potencial de mercado	Receita anual estimada
LP-284 (tratamento do câncer)	Potencial de mercado de US $ 500 milhões	Receita anual projetada de US $ 50-100 milhões
LP-300 (terapêutica oncológica)	Potencial de mercado de US $ 300 milhões	Receita anual projetada de US $ 30-60 milhões

Monetização da propriedade intelectual

O portfólio de propriedade intelectual da Lantern Pharma representa uma oportunidade significativa de geração de receita.

• Número total de patentes: 12
• Receita potencial de licenciamento de IP: US $ 5 a 10 milhões anualmente
• Duração da proteção de patentes: 15-20 anos

Oportunidades de financiamento de concessão e pesquisa

As fontes de financiamento de pesquisa contribuem para a estratégia de diversificação de receita da Lantern Pharma.

Fonte de financiamento	Valor anual de financiamento	Foco na pesquisa
Institutos Nacionais de Saúde (NIH)	US $ 1,5-2,5 milhão	Pesquisa de oncologia
Departamento de Defesa	US $ 1-1,5 milhões	Inovação do tratamento do câncer

Lantern Pharma Inc. (LTRN) - Canvas Business Model: Value Propositions

You're looking at the core reasons why investors and partners would choose Lantern Pharma Inc. (LTRN) over traditional drug development paths. It all boils down to speed, precision, and the power of their AI platform, RADR®.

The value proposition centers on fundamentally changing the economics of oncology drug development. Instead of the industry standard, Lantern Pharma suggests they can advance newly developed drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years, costing approximately $1.0 - $2.5 million per program. This is the concrete data supporting the claim of accelerating timelines and reducing cost compared to industry norms.

Precision Medicine Approach and AI-Driven Biomarkers

Lantern Pharma's approach is about targeting hard-to-treat cancers with drugs selected by AI for specific patient populations. This precision is validated in their lead candidate, LP-184, which targets patients with DNA damage repair (DDR) deficiencies.

Here are the key statistical outcomes from the LP-184 Phase 1a trial:

• The trial involved 63 heavily pre-treated patients with advanced solid tumors.
• It demonstrated a 48% clinical benefit rate at or above the therapeutic dose threshold.
• The key predictive biomarker identified by the RADR® platform is PTGR1.
• Over 87% of Phase 1a patients exceeded the PTGR1 bioactivation threshold.
• The trial established a clear recommended Phase 2 dose of 0.39 mg/kg.

Drug Candidates Targeting Large Markets

The pipeline is focused on indications with substantial unmet need and high revenue potential, validated by the AI platform's analysis. LP-184 is positioned as a potential blockbuster, and the company and independent analysts estimate the aggregate annual market opportunity across its targeted indications could exceed $10 billion.

Here's a breakdown of the market potential for LP-184 across the planned precision Phase 1b/2 trials:

Target Indication	Estimated Annual Market Opportunity (USD)	Patient Population Focus
Triple-Negative Breast Cancer (TNBC)	Exceeding $4 billion	Recurrent TNBC
NSCLC with STK11/KEAP1 Co-mutations	Approaching $1.5 billion	Biomarker-defined subset
Recurrent Glioblastoma (GBM)	Part of a combined potential exceeding $7 billion	First recurrent GBM
Aggregate Potential (Initial Indications)	Exceeding $10 billion to $12 billion	Multiple targeted indications

AI Tools for High-Accuracy Prediction

Lantern Pharma offers external value through its deployed AI modules, such as PredictBBB.ai™, which directly tackles a major bottleneck in CNS drug development. This tool addresses the fact that traditionally, only 2-6% of small-molecule drugs successfully cross the blood-brain barrier.

The performance metrics for the publicly released PredictBBB.ai™ module are quite strong:

Metric	Reported Value
Prediction Accuracy	94%
Sensitivity	95%
Specificity	89%
Processing Speed	Up to 100,000 molecules per hour

Rescuing and Repositioning Shelved Drug Candidates

The RADR® platform provides new insights for existing or shelved assets. This is evident in the progress of LP-284, which exploited a synthetic lethal mechanism in aggressive B-cell cancers. In one case, a patient with Grade 3 diffuse large B-cell lymphoma achieved a complete metabolic response after only two cycles of LP-284, despite having failed R-CHOP chemotherapy, CAR-T therapy, and bispecific antibody therapy. This demonstrates the platform's ability to find new utility for drug candidates.

The platform itself leverages over 200 billion oncology-focused data points and a library of over 200+ advanced machine learning algorithms to drive these discoveries.

Lantern Pharma Inc. (LTRN) - Canvas Business Model: Customer Relationships

High-touch, scientific engagement with clinical investigators and KOLs

• Hosting a KOL-led scientific webinar on LP-184 Phase 1a results on November 20, 2025, featuring Dr. Igor Astsaturov from Fox Chase Cancer Center.
• Presentation of LP-284 clinical data at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress (October 14-17, 2025) generated interest from biopharma companies and clinical investigators.

B2B licensing and collaboration agreements for the RADR® AI platform

The RADR® AI platform is being positioned for commercial use, with plans to launch select modules for the broader drug development community. The platform has been validated in natural clinical trials with LP-184, LP-284, and with Actuate Therapeutics.

RADR® Platform Metric	Value as of Late 2025
Oncology-focused data points leveraged	Over 200 billion
Advanced ML algorithms library size	200+
PredictBBB.ai™ accuracy for BBB permeability	94.1%
PredictBBB.ai™ sensitivity	95%
PredictBBB.ai™ specificity	89%
Percentage of small-molecule drugs crossing BBB (Industry Challenge Addressed)	Only 2-6%

Investor relations and capital raising through public market communications

Lantern Pharma Inc. communicates financial health and development progress to the investment community, which influences capital access. The company noted the need for substantial additional funding in the near future.

Financial Metric (as of late 2025)	Amount/Value
Cash, cash equivalents, and marketable securities (Q3 2025, September 30)	Approximately $12.4 million
Expected operating runway based on current cash	Into approximately Q3 2026
Cash, cash equivalents, and marketable securities (End of 2024, December 31)	Approximately $24.0 million
Net Loss (Q3 2025)	$4.2 million
Net Loss (Q3 2024)	$4.5 million
Stock Price (Pre-market trading after Q3 2025 results)	$3.61 per share
Total funding raised historically	$7.12M
Total funding rounds	5

Regulatory engagement with the FDA for guidance and accelerated pathways

The company actively engages the U.S. Food and Drug Administration (FDA) to define clinical pathways, resulting in specific designations and protocol clearances for its drug candidates.

• Completed a Type C meeting with the FDA for the pediatric CNS cancer trial (ATRT), receiving critical guidance on trial design.
• Planned submission of an Investigational New Drug (IND) application amendment incorporating FDA guidance, with trial initiation targeted for Q1 2026.
• LP-184 received Orphan Drug Designation from the FDA in 2023.
• LP-184 received Fast Track Designation from the FDA in 2024 for Glioblastoma Multiforme (GBM) and Triple-Negative Breast Cancer (TNBC).
• LP-184 received FDA clearance for a Phase 1b/2 trial in NSCLC with KEAP1 and/or STK11 mutations (announced May 12, 2025).
• LP-184 received FDA clearance for a Phase 1b/2 trial in TNBC (announced May 5, 2025).
• LP-284 for Hematologic Cancers was under review by the FDA as of October 28, 2025.

Lantern Pharma Inc. (LTRN) - Canvas Business Model: Channels

You're looking at how Lantern Pharma Inc. (LTRN) gets its drug candidates and its AI technology out to the world, which is a mix of physical trial sites and digital dissemination channels as of late 2025.

The delivery of drug candidates is anchored in global clinical trial sites, which is where the action is right now. The Phase 2 HARMONIC™ trial, for instance, is running across sites in the United States, Japan, and Taiwan. To be specific about the Asian expansion, Lantern announced the completion of enrollment in Japan for the HARMONIC™ trial across five clinical sites in Japan, which included the National Cancer Center Tokyo.

For the RADR® AI modules, the channel is a direct business development approach, signaling commercial readiness. The company showcased the platform's capabilities at the inaugural AI for Biology and Medicine symposium at UNT, positioning the modules as deployable tools for biopharma partners. While specific licensing revenue for 2025 isn't public, the focus is on demonstrating the platform's value through metrics like its 94.1% accuracy for blood-brain barrier permeability prediction.

Regarding future pharmaceutical distribution networks upon drug approval, this remains a forward-looking channel. Currently, the company is focused on advancing its pipeline through clinical trials and securing regulatory guidance, such as the FDA Type C meeting completion for the pediatric CNS cancer trial, which sets the stage for future commercialization pathways rather than detailing established distribution agreements for approved products in 2025.

Dissemination of scientific data, which is crucial for validation and future partnerships, happens through peer-reviewed channels and major medical meetings. This is how they communicate the progress of drug candidates like LP-284 and LP-300.

Here's a look at the key channels and associated hard numbers we have from the Q3 2025 reporting period:

Channel Component	Metric/Location Detail	Associated Value/Count
Global Clinical Trial Sites (LP-300)	Geographic Presence	US, Japan, Taiwan
Global Clinical Trial Sites (LP-300)	Completed Enrollment Sites in Japan	5 clinical sites
RADR® AI Platform Data Scale	Oncology-Focused Data Points	Over 200 billion
RADR® AI Platform Metric (PredictBBB.ai™)	Blood-Brain Barrier Prediction Accuracy	94.1%
RADR® AI Platform Metric (Screening Speed)	Molecular Candidates Screened per Week	200,000
Scientific Dissemination	LL&M Congress Presentation	25th Annual LL&M Congress

The scientific community engagement channels include specific events where data was presented:

• LP-300 preliminary Phase 2 data presented at the 66th Annual Meeting of the Japan Lung Cancer Society.
• LP-284 clinical data showcased at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress.
• KOL-hosted scientific webinar on LP-184 Phase 1a results scheduled for November 20, 2025.
• The company plans further clinical and patient data for LP-300 in a December 2025 webinar.

The direct business development team is focused on leveraging the AI platform's validated capabilities. For example, the LP-184 Phase 1a trial met all primary endpoints, showing a 48% clinical benefit rate in evaluable patients at or above the therapeutic dose threshold, which strengthens the position for any future licensing discussions around that asset.

Lantern Pharma Inc. (LTRN) - Canvas Business Model: Customer Segments

You're looking at the core patient and partner groups Lantern Pharma Inc. (LTRN) is targeting with its precision oncology pipeline and its AI platform, RADR®. Honestly, the strategy is about hyper-focusing on specific genetic profiles where the unmet need is highest, which is where their AI really shines.

The primary patient segments are defined by the biomarker-selected indications for their lead drug candidates, LP-184 and LP-300. For instance, the market opportunity for just Triple-Negative Breast Cancer (TNBC) is estimated to be in excess of $4 billion annually.

Here's a breakdown of the key customer groups Lantern Pharma Inc. is serving as of late 2025:

• Cancer patients with high unmet need, biomarker-selected solid tumors (e.g., TNBC, GBM)
• Cancer patients with rare pediatric CNS cancers (via Starlight Therapeutics)
• Biopharma and biotech companies seeking to accelerate their R&D using AI
• Oncology researchers and academic institutions for AI platform modules

The patient populations targeted for LP-184 alone-TNBC, NSCLC with STK11/KEAP1 co-mutations, bladder cancer, and recurrent Glioblastoma (GBM)-represent a combined annual market potential exceeding $7 billion. That's a serious focus area.

Biomarker-Selected Solid Tumor Patients

This segment is driven by the clinical development of LP-184, which successfully completed its Phase 1a trial enrolling 63 heavily pre-treated patients. The planned Phase 1b/2 trials are highly specific:

Indication	Patient Population Detail	Planned Phase 1b/2 Enrollment (Approximate)	Estimated Annual Market Opportunity (Global)
Triple-Negative Breast Cancer (TNBC)	HR-deficient TNBC patients; pursuing monotherapy and combination with olaparib	60-64 patients total	Exceeds $4 billion USD
Recurrent Glioblastoma (GBM)	LP-184 plus spironolactone combination, STAR-001	38-39 patients	GBM affects over 13,000 U.S. patients annually
Advanced Urothelial Carcinoma (Bladder Cancer)	Patients with PTGR1-high expression and NER/HR pathway deficiencies (Investigator-led trial in Denmark)	27-39 patients	About $500 million-plus

You also have the LP-300 segment, focusing on never-smokers with Non-Small Cell Lung Cancer (NSCLC). This population is about 15% of new lung cancer cases in the U.S., but significantly higher in East Asia at 33% to 40%.

Rare Pediatric CNS Cancer Patients

This group is being addressed through the spin-off entity, Starlight Therapeutics, which is focused on CNS-focused oncology. Lantern Pharma Inc. has secured four Rare Pediatric Disease Designations for LP-184 in conditions including Atypical Teratoid Rhabdoid Tumor (ATRT). The company received regulatory guidance following an FDA Type C meeting for the planned pediatric CNS cancer trial in ATRT.

Biopharma and Biotech Companies

These entities are customers for Lantern Pharma Inc.'s AI technology, often through co-development agreements, IP licensing, or equity participation. The RADR® platform is positioned as a tool to dramatically reduce costs and timelines in drug development.

The platform's commercial readiness is a key offering, with select RADR® AI modules planned for commercial availability and launch. The AI business itself is positioned as a potential standalone revenue stream worth 'several hundred million'.

Specific examples of current biopharma customers leveraging RADR® include:

• Actuate Therapeutics: RADR® predicts patient response with accuracy exceeding 88% for Elraglusib.
• Oregon Therapeutics: Leveraging RADR® to optimize PDI inhibitor XCE853 development.
• TTC Oncology: RADR® is accelerating development of TTC-352, a Phase 2 clinical trial-ready drug candidate.

Oncology Researchers and Academic Institutions

This segment uses specific, commercially ready AI modules that are available as open-access services for collaborators. The RADR® platform itself, as of Q1 2025, leveraged approximately 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms.

One key module, predictBBB.ai, achieves 94.1% accuracy in predicting blood-brain barrier permeability and can screen 200,000 drug candidates in under a week. Another module, LBx-AI, shows an accuracy of 0.76 Pearson correlation in predicting PD-L1 expression levels from circulating tumor DNA.

If you're thinking about the overall pipeline progress, the combined annual market potential across all AI-driven product candidates is estimated to be over $15 billion USD.

Finance: draft 13-week cash view by Friday.

Lantern Pharma Inc. (LTRN) - Canvas Business Model: Cost Structure

You're looking at where Lantern Pharma Inc. is spending its capital to drive its AI-first oncology pipeline forward. Honestly, for a clinical-stage biotech, the cost structure is dominated by the science, which is exactly what you'd expect.

Heavy Research and Development (R&D) expenses are the biggest line item, reflecting the core mission. For the third quarter ended September 30, 2025, R&D expenses were approximately $2.4 million. This compares to R&D expenses of approximately $3.7 million for the same quarter in 2024. The company reported a net loss of $4.2 million for Q3 2025.

The cost structure is heavily weighted toward advancing the drug candidates through the clinic and preparing for the next stages of development. This covers clinical trial execution and manufacturing costs for drug candidates like LP-184, which just completed enrollment in its Phase 1a trial. The company is advancing development plans for LP-184 in high-value indications, including Triple-Negative Breast Cancer (TNBC) and NSCLC with STK11/KEAP1 Co-mutations. The AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.

Next up are the General and Administrative (G&A) expenses. For Q3 2025, these were approximately $1.9 million. The decrease in R&D expenses for the quarter was partially offset by increases in licensing expenses of approximately $31,000.

A significant portion of the operating spend goes into the proprietary technology underpinning the entire model: investment in AI platform maintenance, data acquisition, and patent costs. Lantern Pharma's RADR® platform leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms. This technology is what allows them to advance new drug programs from initial AI insights to first-in-human clinical trials in 2-3 years at a reported cost of approximately $1.0 - $2.5 million per program.

Finally, you have the payroll and compensation expenses for a specialized team. The R&D expense reduction in Q3 2025 compared to Q3 2024 was partially attributable to decreases in payroll and compensation expenses of approximately $224,000. This reflects the cost of maintaining the specialized talent needed to run both the clinical trials and the complex AI infrastructure.

Here's a quick look at the key financial figures anchoring this cost base as of the end of Q3 2025:

Financial Metric	Amount (Millions USD)	Period/Date
R&D Expenses	2.4	Q3 2025
G&A Expenses	1.9	Q3 2025
Total Operating Expenses	4.25	Q3 2025
Net Loss	4.2	Q3 2025
Cumulative Net Loss	13.05	First Three Quarters 2025
Cash, Cash Equivalents, and Marketable Securities	12.4	September 30, 2025

The cash position of $12.4 million as of September 30, 2025, was expected to fund operations into Q3 2026. The cost drivers break down into these main categories:

• R&D spend for clinical trial execution.
• G&A for general operations and overhead.
• Costs associated with the RADR® AI platform.
• Salaries for the specialized scientific and technical staff.

To be fair, managing these costs is critical; the company is actively managing its burn rate, evidenced by the R&D expense decrease year-over-year for the quarter. Finance: draft 13-week cash view by Friday.

Lantern Pharma Inc. (LTRN) - Canvas Business Model: Revenue Streams

Lantern Pharma Inc.'s revenue generation model as of late 2025 is heavily weighted toward non-operational financing and the future monetization of its clinical pipeline and technology platform, rather than immediate product sales.

Minimal current revenue; primary focus is on capital appreciation through pipeline milestones

Honestly, the current top-line revenue picture for Lantern Pharma Inc. is minimal. As of September 30, 2025, the company reports a trailing 12-month revenue of null. An AI Analyst assessment for the third quarter of 2025 highlighted challenging financial outlook due to zero revenue and ongoing cash flow concerns, which necessitates additional funding to continue operations. The primary financial driver remains capital appreciation contingent upon achieving significant clinical and regulatory milestones for its drug candidates.

The company maintains a disciplined approach to capital management, which is crucial given the lack of current sales. Cash, cash equivalents, and marketable securities stood at approximately $12.4 million as of September 30, 2025. This figure is down from approximately $24.0 million at the end of 2024. This cash position is expected to fund operating expenses and capital expenditure requirements at least into June 2026.

The potential value embedded in the pipeline serves as a proxy for future revenue events. Consider the estimated market potentials:

• LP-184 potential market: $10-12 billion USD in annual revenue.
• LP-300 market opportunity in never-smokers with NSCLC: Over $4 billion annually.
• Combined annual market potential across the AI-driven pipeline (as of early 2025): Over $15 billion USD.

Future revenue from licensing or collaboration fees for drug candidates

Future revenue is anticipated to materialize through strategic licensing or collaboration agreements for its clinical-stage drug candidates, such as LP-300 and LP-184. The company is actively exploring these partnering opportunities to maximize commercial potential, especially for LP-300 across multiple geographies. The advancement of LP-184 through Phase 1a, establishing the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), positions it for Phase 1b/2 trials in indications like recurrent triple negative breast cancer (TNBC) and recurrent bladder cancer, which strengthens its attractiveness for potential deals.

Sales and licensing of commercial RADR® AI platform modules to external partners

The proprietary RADR® platform is a distinct revenue-generating asset. Lantern Pharma Inc. is moving toward commercializing select modules of this platform for the broader scientific and research community. The platform itself leverages over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms. Specific modules are being readied for external use, such as the predictBBB.ai™ module, which achieves 94.1% accuracy for blood-brain barrier permeability prediction and can screen 200,000 molecular candidates in under one week. The company is planning commercial availability and launch of these modules, with continued collaboration discussions advancing.

The cost to develop these assets provides context for their potential licensing value. On average, newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials at approximately $1.0 - $2.5 million per program.

Equity financing (e.g., ATM sales agreement for up to $15.53 million) to fund operations

To bridge the gap until potential product-based revenues materialize, Lantern Pharma Inc. utilizes equity financing as a key source of operational funding. On July 3, 2025, the company entered into an At-The-Market (ATM) Sales Agreement with ThinkEquity LLC. This agreement allows Lantern Pharma Inc. to offer and sell shares of common stock up to a maximum aggregate offering price of $15,530,000, or $15.53 million, as needed.

The reliance on this funding mechanism is evident in the cash burn between reporting periods. Here's a quick look at the cash position changes:

Date	Cash, Cash Equivalents, and Marketable Securities (Approximate)
December 31, 2024	$24.0 million
March 31, 2025	$19.7 million
June 30, 2025	$15.9 million
September 30, 2025	$12.4 million

Potential milestone payments from future partnerships

Milestone payments represent contingent revenue streams tied directly to the success of the drug candidates in clinical development and regulatory progression. For instance, the LP-184 Phase 1a trial achieved all primary endpoints with a 48% clinical benefit rate in evaluable patients, which is a significant value-creation catalyst that supports future partnership discussions. Also, the company received FDA guidance for its pediatric CNS cancer trial, another milestone that de-risks the asset and enhances its potential for upfront payments, option fees, or milestone payments upon entering into a formal collaboration or licensing deal.